Doximity (NASDAQ:DOCS) Issues Quarterly Earnings Results

Doximity (NASDAQ:DOCS) released its quarterly earnings data on Thursday. The company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.01, Briefing.com reports. Doximity had a return on equity of 21.75% and a net margin of 36.60%.The company’s quarterly revenue was up 9.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.45 EPS.

Doximity Stock Performance

DOCS stock opened at $33.30 on Friday. Doximity has a one year low of $32.66 and a one year high of $85.21. The firm has a market cap of $6.27 billion, a price-to-earnings ratio of 33.30, a PEG ratio of 4.10 and a beta of 1.39. The firm has a 50-day simple moving average of $43.16 and a two-hundred day simple moving average of $56.92.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on DOCS shares. Truist Financial set a $62.00 target price on shares of Doximity in a report on Thursday, January 8th. Piper Sandler reissued an “overweight” rating on shares of Doximity in a research note on Friday. The Goldman Sachs Group raised Doximity from a “neutral” rating to a “buy” rating and set a $49.00 price objective for the company in a research note on Friday, January 9th. Canaccord Genuity Group set a $48.00 target price on Doximity in a research report on Thursday, January 8th. Finally, JPMorgan Chase & Co. restated an “underweight” rating and set a $62.00 price target on shares of Doximity in a report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.95.

Institutional Investors Weigh In On Doximity

A number of hedge funds and other institutional investors have recently bought and sold shares of DOCS. Advisory Services Network LLC purchased a new position in Doximity in the third quarter worth $111,000. Scientech Research LLC purchased a new position in Doximity during the 3rd quarter worth $206,000. Brooklyn Investment Group increased its position in Doximity by 123.4% during the 3rd quarter. Brooklyn Investment Group now owns 2,855 shares of the company’s stock valued at $209,000 after buying an additional 1,577 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new position in Doximity during the 3rd quarter valued at about $222,000. Finally, Amundi purchased a new stake in Doximity in the third quarter valued at about $223,000. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Doximity declared that its board has initiated a stock repurchase plan on Thursday, February 5th that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Key Stories Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Q3 results beat consensus on both EPS and revenue: $0.46 EPS (vs. ~$0.45) and roughly $185.1M revenue (up ~10% YoY), with strong profitability (net margin ~36.6%). This shows the core business remains profitable and growing. Doximity Announces Fiscal 2026 Third Quarter Financial Results
• Positive Sentiment: User engagement and product traction remain healthy: the company highlighted record engagement (over 1M quarterly active prescribers) and a sequential jump in workflow-product users, indicating demand for its clinical workflow and professional network offerings. Doximity Announces Fiscal 2026 Third Quarter Financial Results
• Neutral Sentiment: Analyst write-ups dig into metric details (growth rates, engagement vs. estimates) that can guide revisions; they confirm the quarter beat but focus investor attention on forward trends. Here’s What Key Metrics Tell Us About Doximity (DOCS) Q3 Earnings
• Negative Sentiment: Management’s forward guidance disappointed: Q4 revenue was guided to ~$143.0–$144.0M vs. consensus near $150.2M, and FY26 revenue guidance (~$642.5–$643.5M) was marginally below Street estimates — the guidance miss is the main driver of the sell-off. Doximity Announces Fiscal 2026 Third Quarter Financial Results
• Negative Sentiment: Market reaction was sharp: shares plunged after-hours and trading volume spiked as investors sold into the weaker guidance despite the quarter’s beats. Momentum and multiple compression are likely contributors to today’s downside. Doximity Stock Is Collapsing After Hours: Here’s Why

Doximity Company Profile

Doximity, Inc, headquartered in San Francisco, California, operates the leading professional medical network for healthcare professionals in the United States. Founded in 2011 by Jeff Tangney and Shari Buck, the company set out to create a secure digital environment where physicians, nurse practitioners and physician assistants can collaborate, share information and stay current with clinical news. Doximity went public in June 2021 and trades on the NASDAQ under the ticker symbol “DOCS.”

The core offering of Doximity is its HIPAA-compliant communication platform, which includes a secure messaging system, digital fax services and telehealth capabilities.